

Fig. 1-A




Fig. 1-B




Fig. 1-C

Size: 0.6360 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN




Fig. 2-A

Size: 1.7840 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN




Fig. 2-B

Size: 1.4230 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN




Fig. 2-C




Fig. 2-D

Sample Weight: 15.300 mg

Comment:


N-Propyl Alcohol etchale 1
unsealed pan

Fig. 2-E




Fig. 3-A




Fig. 3-B




Fig. 3-C

12/55




Fig. 3-D




Fig. 4




Fig. 5




Fig. 6-A




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14





Fig. 15



Purity

A: Cooling Rate
B: Purity
C: End Point

Fig. 16




Fig. 17




Fig. 18




Fig. 19

Form
A: Cooling Rate
B: Purity
C: End Point




Fig. 20




Fig. 21




Fig. 22

Systolic Blood Pressure in Angiotensin II- or Vehicle-Infused Rats





Fig. 23

Eplerenone Prevents the Vascular Inflammatory Lesions in Angiotensin II/Salt Hypertensive Rats




Vehicle

Eplerenone

Fig. 24

COX-2 is Not Expressed in the Heart of 1% NaCl-Drinking Rats



1% NaCl

FIGURE 25

Angiotensin II/NaCl Treatment Induces COX-2 Expression in the Media of Coronary Arteries in Rats



Angiotensin II + NaCl

FIGURE 26


Eplerenone Prevents COX-2 Expression in Coronary
Arteries in Angiotensin II/Salt Hypertensive Rats



FIGURE 27

Angiotensin II + NaCl + Eplerenone

Osteopontin is Not Expressed in the Normal Heart




Saline-Drinking Control

FIGURE 28

Eplerenone Prevents Osteopontin Expression in Coronary Arteries of Aldosterone/Salt/Uninephrectomized Rats




Aldosterone/Salt with
Eplerenone




Aldosterone/Salt

FIGURE 29

Eplerenone Prevents Myocardial Osteopontin Upregulation in Aldosterone/Salt Hypertensive Rats




Eplerenone Prevents Myocardial COX-2 Upregulation in Aldosterone/Salt Hypertensive Rats




*** $P < .001$ vs NaCl
†† $P < .01$ vs Aldo/NaCl

Eplerenone FIGURE 31

COX-2 and Osteopontin are Co-Expressed in Similar
Regions in the Coronary Arterial Wall



Osteopontin



COX-2

FIGURE 33

Potential Mechanisms of Aldosterone-Induced Vascular Inflammation and Injury




FIGURE 34

Urinary Protein Excretion in Saline-Drinking Stroke-Prone SHR




FIGURE 35

Histopathologic Scores for Renal Injury in Saline-Drinking Stroke-Prone SHR

	Vehicle (n=8)	Capt (n=10)	Capt ALDO (n=7)	Capt Ang II (n=7)	Capt+Ang II+ Eplerenone (n=7)
Renal arteriopathy (lesions/100 glom.)	18±3**	0±0	15±1**	16±2**	3.6±1**,##
Glomerular damage (lesions/100 glom.)	24±3**	0±0	26±1**	15±3**	3.2±1**,##

** P<.001 vs Captopril

P<.001 vs Captopril & Ang II

FIGURE 36

Eplerenone Prolongs Survival and Protects Against Stroke in Saline-Drinking Stroke-Prone SHR






FIGURE 37

Eplerenone Protects Against Cerebral Injury in Saline-Drinking Stroke-Prone SHR



Eplerenone-Treated
SHRSP



Vehicle-Treated
SHRSP

FIGURE 38

Time-Course Expression of Myocardial COX-2 in Aldosterone-Salt Hypertensive Rats




FIGURE 39

Time-Course Expression of Myocardial Osteopontin in Aldosterone-Salt Hypertensive Rats




FIGURE 40

Time-Course Expression of Myocardial MCP-1 in Aldosterone-Salt Hypertensive Rats




FIGURE 41

Time-Course Expression of Myocardial ICAM-1 and VCAM-1 in Aldosterone-Salt Hypertensive Rats




FIGURE 42

Eplerenone Reduces Systolic Blood Pressure





FIG. 43



* $p < 0.05$ vs. Veh
+ $p < 0.05$ vs. Aldo

FIG 44

28 Day Circulating Osteopontin Levels

osteopontin (ng/ml)




FIG. 45




FIG. 46